Conduit and AstraZeneca Partner to Advance Phase II Trials for Autoimmune Treatments

Conduit Pharmaceuticals and AstraZeneca have teamed together to license the development of AZD5904, a myeloperoxidase inhibitor (MPO), and AZD1656 and AZD5658, all HK-4 glucokinase activators. These drugs have advanced through Phase 1 clinical studies conducted by AstraZeneca. Conduit intends to carry out Phase II clinical studies for autoimmune illnesses in 2024; these conditions are thought to impact 10% of the population.

Exclusive licenses for AZD1656 and AZD5658 for all human indications, as well as an exclusive license for AZD5904 for use in idiopathic male infertility, will be granted to Conduit by AstraZeneca. AstraZeneca will also receive a portion of licensing income from Conduit. AstraZeneca will provide Conduit with specific amounts of AZD1656, AZD5658, and AZD5658 from its stockpile in addition to exchanging pre-clinical and clinical data on the assets.

The License Agreement includes provisions for the transfer of know-how related to AZD1656, AZD5658, and AZD5904 from AstraZeneca to Conduit. AstraZeneca has been granted a right of first negotiation to develop, manufacture, and commercialize the licensed compounds if Conduit seeks to assign, license, or grant such rights to a third party. Conduit plans to analyze existing clinical data and initiate Phase II trials, aiming to bring innovative new medicines to patients facing substantial unmet needs.